- Joined
- Mar 21, 2008
- Messages
- 27
frag177-191 176-191 does not compete with the same receptors as GH......
frag will not make you insulin resist.
HUGE POTENTIAL FOR THE TREATMENT OF OBESITY
International Journal of Obesity (2001) 25, 1442 – 1449
OBJECTIVE: To observe the chronic effects of human growth hormone (hGH) and AOD9604 (a C-terminal fragment of hGH) on
body weight, energy balance, and substrate oxidation rates in obese (ob=ob) and lean C57BL=6Jmice. In vitro assays were used
to confirm whether the effects of AOD9604 are mediated through the hGH receptor, and if this peptide is capable of cell
proliferation via the hGH receptor.
METHOD: Obese and lean mice were treated with hGH, AOD or saline for 14 *days using mini-osmotic pumps. Body weight,
caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol were
measured before and after treatment. BaF-BO3 cells transfected with the hGH receptor were used to measure in vitro 125I-hGH
receptor binding and cell proliferation.
RESULTS: Both hGH and AOD significantly reduced body weight gain in obese mice. This was associated with increased in vivo
fat oxidation and increased plasma glycerol levels (an index of lipolysis). Unlike hGH, however, AOD9604 did not induce
hyperglycaemia or reduce insulin secretion. AOD9604 does not compete for the hGH receptor and nor does it induce cell
proliferation, unlike hGH.
CONCLUSIONS: Both hGH and its C-terminal fragment reduce body weight gain, increase fat oxidation, and stimulate lipolysis
in obese mice, yet AOD9604 does not interact with the hGH receptor. Thus, the concept of hGH behaving as a pro-hormone is
further confirmed. This data shows that fragments of hGH can act in a manner novel to traditional hGH-stimulated pathways.
**AOD9604 HGHFRAG177-191
frag will not make you insulin resist.
HUGE POTENTIAL FOR THE TREATMENT OF OBESITY
International Journal of Obesity (2001) 25, 1442 – 1449
OBJECTIVE: To observe the chronic effects of human growth hormone (hGH) and AOD9604 (a C-terminal fragment of hGH) on
body weight, energy balance, and substrate oxidation rates in obese (ob=ob) and lean C57BL=6Jmice. In vitro assays were used
to confirm whether the effects of AOD9604 are mediated through the hGH receptor, and if this peptide is capable of cell
proliferation via the hGH receptor.
METHOD: Obese and lean mice were treated with hGH, AOD or saline for 14 *days using mini-osmotic pumps. Body weight,
caloric intake, resting energy expenditure, fat oxidation, glucose oxidation, and plasma glucose, insulin and glycerol were
measured before and after treatment. BaF-BO3 cells transfected with the hGH receptor were used to measure in vitro 125I-hGH
receptor binding and cell proliferation.
RESULTS: Both hGH and AOD significantly reduced body weight gain in obese mice. This was associated with increased in vivo
fat oxidation and increased plasma glycerol levels (an index of lipolysis). Unlike hGH, however, AOD9604 did not induce
hyperglycaemia or reduce insulin secretion. AOD9604 does not compete for the hGH receptor and nor does it induce cell
proliferation, unlike hGH.
CONCLUSIONS: Both hGH and its C-terminal fragment reduce body weight gain, increase fat oxidation, and stimulate lipolysis
in obese mice, yet AOD9604 does not interact with the hGH receptor. Thus, the concept of hGH behaving as a pro-hormone is
further confirmed. This data shows that fragments of hGH can act in a manner novel to traditional hGH-stimulated pathways.
**AOD9604 HGHFRAG177-191